Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine

Cell Host and Microbe

Volumn 24, Issue 1, 2018, Pages 18-24

  Coughlan, Lynda ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

B LYMPHOCYTE; DRUG DESIGN; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MOLECULAR IMPRINTING; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY; DRUG DEVELOPMENT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MOLECULAR EVOLUTION; MUTATION; ORTHOMYXOVIRIDAE; VACCINATION; VIROLOGY;

ANTIBODIES, VIRAL; DRUG DEVELOPMENT; EVOLUTION, MOLECULAR; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; ORTHOMYXOVIRIDAE; VACCINATION;

EID: 85049315230     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2018.06.016     Document Type: Review

References (41)

1. Anderson, C.S., Ortega, S., Chaves, F.A., Clark, A.M., Yang, H., Topham, D.J., DeDiego, M.L., Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain. Sci. Rep., 7, 2017, 14614.
2. Andrews, S.F., Huang, Y., Kaur, K., Popova, L.I., Ho, I.Y., Pauli, N.T., Henry Dunand, C.J., Taylor, W.M., Lim, S., Huang, M., Qu, X., Lee, J.-H., Salgado-Ferrer, M., Krammer, F., Palese, P., Wrammert, J., Ahmed, R., Wilson, P.C., Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Trans. Med., 7, 2015, 316ra192.
3. Antrobus, R.D., Coughlan, L., Berthoud, T.K., Dicks, M.D., Hill, A.V., Lambe, T., Gilbert, S.C., Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther. 22 (2014), 668–674.
4. Bruhns, P., Jönsson, F., Mouse and human FcR effector functions. Immunol. Rev. 268 (2015), 25–51.
5. Chen, Z., Zhou, H., Jin, H., The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28 (2010), 4079–4085.
6. Chen, C.-J., Ermler, M.E., Tan, G.S., Krammer, F., Palese, P., Hai, R., Influenza A viruses expressing intra- or inter-group chimeric hemagglutinins. J. Virology 90 (2016), 3789–3793.
7. Cobey, S., Gouma, S., Parkhouse, K., Chambers, B.S., Ertl, H.C., Schmader, K.E., Halpin, R.A., Lin, X., Stockwell, T.B., Das, S.R., Landon, E., Tesic, V., Youngster, I., Pinsky, B.A., Wentworth, D.E., Hensley, S.E., Grad, Y.H., Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012-13. Clin. Infect. Dis., 2018, 10.1093/cid/ciy097 Published online February 20, 2018.
8. Coughlan, L., Sridhar, S., Payne, R., Edmans, M., Milicic, A., Venkatraman, N., Lugonja, B., Clifton, L., Qi, C., Folegatti, P.M., et al. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine 29 (2018), 146–154.
9. DiLillo, D.J., Tan, G.S., Palese, P., Ravetch, J.V., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 20 (2014), 143–151.
10. DiLillo, D.J., Palese, P., Wilson, P.C., Ravetch, J.V., Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126 (2016), 605–610.
11. Doud, M.B., Bloom, J.D., Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses, 8, 2016, E155.
12. Doud, M.B., Lee, J.M., Bloom, J.D., How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat. Commun., 9, 2018, 1386.
13. Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., Lee, J.H., Metlagel, Z., Bujny, M.V., Jongeneelen, M., et al. ). Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
14. Ekiert, D.C., Bhabha, G., Elsliger, M.-A., Friesen, R.H.E., Jongeneelen, M., Throsby, M., Goudsmit, J., Wilson, I.A., Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009), 246–251.
15. Ellebedy, A.H., Jackson, K.J.L., Kissick, H.T., Nakaya, H.I., Davis, C.W., Roskin, K.M., McElroy, A.K., Oshansky, C.M., Elbein, R., Thomas, S., et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat. Immunol. 17 (2016), 1–11.
16. Ellebedy, A.H., Krammer, F., Li, G.-M., Miller, M.S., Chiu, C., Wrammert, J., Chang, C.Y., Davis, C.W., McCausland, M., Elbein, R., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. USA 111 (2014), 13133–13138.
17. Flannery, B., Chung, J.R., Belongia, E.A., McLean, H.Q., Gaglani, M., Murthy, K., Zimmerman, R.K., Nowalk, M.P., Jackson, M.L., Jackson, L.A., et al. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018. MMWR Morb. Mortal. Wkly. Rep. 67 (2018), 180–185.
18. Giles, B.M., Ross, T.M., A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29 (2011), 3043–3054.
19. Gostic, K.M., Ambrose, M., Worobey, M., Lloyd-Smith, J.O., Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354 (2016), 722–726.
20. Hai, R., Krammer, F., Tan, G.S., Pica, N., Eggink, D., Maamary, J., Margine, I., Albrecht, R.A., Palese, P., Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86 (2012), 5774–5781.
21. Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A., Dukes, O., Millett, E.R., Nazareth, I., Nguyen-Van-Tam, J.S., et al., Flu Watch Group. Natural T cell-mediated protection against seasonal and pandemic influenza. results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 191 (2015), 1422–1431.
22. Heaton, N.S., Sachs, D., Chen, C.-J., Hai, R., Palese, P., Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl. Acad. Sci. USA 110 (2013), 20248–20253.
23. Henry Dunand, C.J., Leon, P.E., Kaur, K., Tan, G.S., Zheng, N.Y., Andrews, S., Huang, M., Qu, X., Huang, Y., Salgado-Ferrer, M., et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J. Clin. Invest. 125 (2015), 1255–1268.
24. Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M., Zhu, X., Hoffman, R.M.B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 (2015), 1301–1306.
25. Krause, J.C., Tsibane, T., Tumpey, T.M., Huffman, C.J., Basler, C.F., Crowe, J.E. Jr., A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85 (2011), 10905–10908.
26. Lux, A., Nimmerjahn, F., Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 33:Suppl 1 (2013), S4–S8.
27. Nachbagauer, R., Wohlbold, T.J., Hirsh, A., Hai, R., Sjursen, H., Palese, P., Cox, R.J., Krammer, F., Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88 (2014), 13260–13268.
28. Nachbagauer, R., Liu, W.C., Choi, A., Wohlbold, T.J., Atlas, T., Rajendran, M., Solórzano, A., Berlanda-Scorza, F., García-Sastre, A., Palese, P., et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines, 2, 2017, 26.
29. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
30. Ortiz, J.R., Hickling, J., Jones, R., Donabedian, A., Engelhardt, O.G., Katz, J.M., Madhi, S.A., Neuzil, K.M., Rimmelzwaan, G.F., Southern, J., et al. Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. Vaccine 36 (2017), 932–938.
31. Paules, C.I., Marston, H.D., Eisinger, R.W., Baltimore, D., Fauci, A.S., The Pathway to a Universal Influenza Vaccine. Immunity 47 (2017), 599–603.
32. Pica, N., Hai, R., Krammer, F., Wang, T.T., Maamary, J., Eggink, D., Tan, G.S., Krause, J.C., Moran, T., Stein, C.R., et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. USA 109 (2012), 2573–2578.
33. Rajendran, M., Sun, W., Comella, P., Nachbagauer, R., Wohlbold, T.J., Amanat, F., Kirkpatrick, E., Palese, P., Krammer, F., An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS One, 13, 2018, e0194830.
34. Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., García-Sastre, A., Palese, P., Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1 (2010), 1–9.
35. Thompson, C., Lourenco, J., Walters, A., Obolski, U., Edmans, M., Palmer, D., Kooblall, K., Carnell, G.O., Connor, D., Bowden, T., et al. Identification of an epitope of limited variability under strong immune selection in the haemagglutinin head domain of H1N1 influenza. bioRxiv, 2017, 10.1101/212845 Published November 3, 2017.
36. Tran, E.E., Podolsky, K.A., Bartesaghi, A., Kuybeda, O., Grandinetti, G., Wohlbold, T.J., Tan, G.S., Nachbagauer, R., Palese, P., Krammer, F., Subramaniam, S., Cryo-electron microscopy structures of chimeric hemagglutinin displayed on a universal influenza vaccine candidate. MBio, 7, 2016, e00257.
37. Wang, T.T., Maamary, J., Tan, G.S., Bournazos, S., Davis, C.W., Krammer, F., Schlesinger, S.J., Palese, P., Ahmed, R., Ravetch, J.V., Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162 (2015), 160–169.
38. Wohlbold, T.J., Podolsky, K.A., Chromikova, V., Kirkpatrick, E., Falconieri, V., Meade, P., Amanat, F., Tan, J., tenOever, B.R., Tan, G.S., et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat. Microbiol. 2 (2017), 1415–1424.
39. Wu, N.C., Zost, S.J., Thompson, A.J., Oyen, D., Nycholat, C.M., McBride, R., Paulson, J.C., Hensley, S.E., Wilson, I.A., A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog., 13, 2017, e1006682.
40. Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21 (2015), 1065–1070.
41. Zost, S.J., Parkhouse, K., Gumina, M.E., Kim, K., Diaz Perez, S., Wilson, P.C., Treanor, J.J., Sant, A.J., Cobey, S., Hensley, S.E., Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA 114 (2017), 12578–12583.